Vertex bets USD 10b on endocrinology diversification with Crinetics acquisition

Vertex Pharmaceuticals [has agreed to acquire](https://www.biospace.com/press-releases/vertex-to-acquire-crinetics-pharmaceuticals) San Diego-based Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) for USD 85.00 per share in cash, representing a total equity value of approximately USD 10.0 billion, or USD 8.8 billion net of estimated cash acquired. The acquisition gives Vertex an immediately commercial rare endocrine therapy alongside a Phase III pipeline candidate with multi-billion-dollar sales potential, representing the company's largest strategic expansion beyond cystic fibrosis. Vertex will finance the acquisition using cash on hand and debt, supported by USD 4.5 billion in committed bridge financing. The deal is expected to close in Q3 2026, subject to regulatory approvals and Crinetics shareholder approval. The commercial anchor of the deal is [Palsonify (paltusotine)](https://allsci.com/news/approvals/crinetics-palsonify-adds-eu-approval-for-acromegaly/), the first and only once-daily oral somatostatin receptor type 2 (SST2) nonpeptide agonist approved for adults with acromegaly with inadequate response to surgery or for whom surgery is not an option. The US FDA approved paltusotine in September 2025, and the European Commission granted approval in April 2026. [Paltusotine ](https://app.allsci.com/drugs/ASC-DR-0000000011401-1.0-1759575754)selectively binds SST2 receptors to suppress excess growth hormone and insulin-like growth factor-1 (IGF-1) secretion, offering a differentiated oral alternative to the large-needle intramuscular or deep subcutaneous injectable somatostatin analogues that have historically dominated acromegaly management. Early commercial uptake has been encouraging, with Crinetics reporting more than USD 5 million in Q4 2025 net product revenue, over 200 enrollment forms, and more than 125 unique prescribers. Paltusotine also enjoys first-mover status as the only approved oral therapy in the class. Sweden-based Camurus's injectable candidate CAM2029 (oclaiz), which targets the same indication, has [received repeated FDA complete response letters](https://allsci.com/news/crl/camurus-receives-second-manufacturing-linked-crl-from-fda-for-oclaiz-acromegaly-drug/) linked to manufacturing deficiencies, leaving paltusotine without an approved oral or next-generation injectable competitor in the near term. The second strategic asset is [atumelnant](https://app.allsci.com/drugs/ASC-DR-0000000044603-1.0-1775585065), a once-daily oral ACTH receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) in the adrenal cortex. By directly antagonizing the ACTH receptor, atumelnant inhibits downstream androgen and glucocorticoid production irrespective of ACTH origin, enabling sustained androgen normalization in classic congenital adrenal hyperplasia (CAH) even as glucocorticoid doses are reduced to physiologic replacement levels. Atumelnant is currently enrolling the Phase III CALM-CAH trial in adults and a Phase II/III BALANCE-CAH study in pediatric patients. A Phase I/IIb trial in ACTH-dependent Cushing's syndrome is also enrolling. Vertex projects the two assets could generate more than USD 5 billion in combined peak annual revenue, with the transaction expected to become accretive to non-GAAP operating income in 2029. The deal immediately adds commercial revenue from paltusotine's ongoing launch and positions Vertex to apply its rare disease commercialization infrastructure — built primarily around cystic fibrosis — to a new specialty endocrinology franchise. The acquisition follows an established pattern of M\&A-driven pipeline expansion at Vertex. Povetacicept, a dual BAFF/APRIL pathway inhibitor acquired through the USD 4.9 billion Alpine Immune Sciences transaction in 2024, is [now under FDA review](https://allsci.com/news/approvals/approval-filings/fda-sets-november-decision-date-for-vertexs-povetacicept-in-iga-nephropathy/) for IgA nephropathy, demonstrating Vertex's capacity to advance acquired late-stage assets toward approval. The Crinetics deal is comparable: an outright acquisition of a company with a recently approved commercial product and a Phase III pipeline candidate in a rare disease with high unmet need. Together, paltusotine and atumelnant establish endocrinology as Vertex's next major rare disease franchise, extending the company's strategy of acquiring late-stage assets capable of leveraging its established commercialization infrastructure beyond cystic fibrosis. *** This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: [https://allsci.com/news/](https://allsci.com/news/) --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/vertex-crinetics-acquisition-bets-usd-10-billion)